AroCell signs global license agreement with Roche to develop diagnostic test to help improve cancer diagnosis and disease management. The license agreement gives Roche global sales rights for which AroCell will receive royalties from future sales.
AroCell AB (publ) (First North Stockholm, AROC) announces today that the company has entered a global non-exclusive license agreement with Roche Diagnostics (F. Hoffmann-La Roche Ltd). Roche Diagnostics will develop a test to measure the concentrations of Thymidine Kinase 1 (TK 1) in serum adapted to the company’s fully automated cobas® system. The license agreement gives Roche global sales rights for which AroCell will receive royalties from future sales. The agreement between the parties is confidential and no details about the content of the agreement are disclosed.
Roche will be responsible for the clinical validation of the test prior to the global launch on the high-capacity cobas® platform including the financing. In addition to the licensing agreement, the parties intend to initiate a development collaboration. Discussions are now being held regarding the details of the collaboration.
“We are very proud that Roche Diagnostics has chosen to cooperate with us to further develop our technology to measure the concentration of TK1 in serum. This is a great success for AroCell as a company, but more importantly validates TK1 as a biomarker in cancer diagnosis and disease management,” says Staffan Eriksson, Founder and Research Director at AroCell.
The agreement reinforces Roche Diagnostics’ commitment to continue explore scientific and technological advances and their application in oncology, as well as in other areas such as pre-natal testing and infectious diseases.
About Thymidine Kinase 1 (TK 1)
Oncologists need to monitor tumor growth during cancer treatment. AroCell has developed a test, the TK 210 ELISA for measuring the enzyme TK1, which is a protein that is elevated in the blood when there is increased cell turnover (cell growth and cell death) within the patient. A malignant tumor has high cell turnover and TK1 leaks out into the blood. A test for measuring TK1 therefore has a great potential clinical value.
Jan Stålemark, CEO.
Phone: +46 706–926 206
AroCell is obliged to make public information pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication through Jan Stålemark, 08:59 CET on April 24, 2018.
AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. The AroCell share (AROC) is listed on Nasdaq First North. For more information, please see www.arocell.com.